Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29551865 | 1.00 | CASR (0.62) | CASRLMNAKMT2AMEN1TDP1 | |
| SCHEMBL607183 | 1.00 | CASR (0.62) | CASRLMNAKMT2AMEN1TDP1 | |
| SCHEMBL14469768 | 0.92 | CASR (0.58) | CASRLMNAKMT2AMEN1TDP1 | |
| Cadaverine Tartrate SCHEMBL5825857 | 0.90 | KMT2A (0.59) | CASRLMNAKMT2AMEN1TDP1 | |
| Cadaverine Tartrate SCHEMBL5825862 | 0.90 | KMT2A (0.59) | CASRLMNAKMT2AMEN1TDP1 | |
| Trifluoroacetic Acid SCHEMBL28937395 | 0.89 | CASR (0.61) | CASRLMNAKMT2AMEN1TDP1 | |
| Trifluoroacetic Acid SCHEMBL29551765 | 0.89 | CASR (0.61) | CASRLMNAKMT2AMEN1TDP1 | |
| SCHEMBL13868189 | 0.88 | CASR (0.73) | CASRLMNAKMT2AMEN1TDP1 | |
| SCHEMBL3921801 | 0.86 | CASR (0.67) | CASRLMNAKMT2AMEN1TDP1 | |
| SCHEMBL13868174 | 0.86 | CASR (0.78) | CASRLMNAKMT2AMEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116730993-A | Teranavir intermediate and preparation method of Teranavir | 浙江科技学院 | 2023-09-12 | — | — | CN | disclosed |
| EP-1481961-B1 | PROCESS FOR PRODUCING (R)-3-HYDROXY-3-(2-PHENYLETHYL)HEXANOIC ACID AND ITS INTERMEDIATE | SUMITOMO CHEMICAL CO (JP) | 2009-11-25 | — | — | EP | disclosed |
| EP-1481961-B1 | PROCESS FOR PRODUCING (R)-3-HYDROXY-3-(2-PHENYLETHYL)HEXANOIC ACID AND ITS INTERMEDIATE | SUMITOMO CHEMICAL CO (JP) | 2009-11-25 | — | — | EP | disclosed |
| EP-1894912-B1 | Process for producing racemic 3-hydroxy-3-(2-phenylethyl) hexanoic acid ester | SUMITOMO CHEMICAL CO (JP) | 2009-08-05 | — | — | EP | disclosed |
| EP-1894912-B1 | Process for producing racemic 3-hydroxy-3-(2-phenylethyl) hexanoic acid ester | SUMITOMO CHEMICAL CO (JP) | 2009-08-05 | — | — | EP | disclosed |
| EP-1894912-A1 | Process for producing racemic 3-hydroxy-3-(2-phenylethyl) hexanoic acid ester | Sumitomo Chemical Company, Limited (JP) | 2008-03-05 | — | — | EP | disclosed |
| EP-1894912-A1 | Process for producing racemic 3-hydroxy-3-(2-phenylethyl) hexanoic acid ester | Sumitomo Chemical Company, Limited (JP) | 2008-03-05 | — | — | EP | disclosed |
| JP-2006225272-A | (R)-N-(3,4-DIMETHOXYBENZYL)-1-PHENYLETHYLAMINE L-TARTRATE AND METHOD OF PURIFYING (R)-N-(3,4-DIMETHOXYBENZYL)-1-PHENYLETHYLAMINE USING THE SAME | SUMITOMO CHEMICAL CO LTD | 2006-08-31 | — | — | JP | disclosed |
| CN-1821190-A | Purifying method of (r)-n-(3,4-dimethoxy benzyl)-1-phenylethylamine l-tartrate and purifying method of (r)-n-(3,4-dimethoxy benzyl)-1-phenylethylamine | SUMITOMO CHEMICAL CO (JP) | 2006-08-23 | — | — | CN | disclosed |
| CN-1821190-A | Purifying method of (r)-n-(3,4-dimethoxy benzyl)-1-phenylethylamine l-tartrate and purifying method of (r)-n-(3,4-dimethoxy benzyl)-1-phenylethylamine | SUMITOMO CHEMICAL CO (JP) | 2006-08-23 | — | — | CN | disclosed |
| US-7038075-B2 | Production method of racemic 3-hydroxy-3-(2-phenylethyl)hexanoic acid C1-6 alkyl ester | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-05-02 | — | — | US | disclosed |
| US-20060020023-A1 | Racemization method | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-26 | — | — | US | disclosed |
| US-20060016683-A1 | Photoracamization method | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-26 | — | — | US | disclosed |
| US-20060020022-A1 | Enantioselective separation method | PHARMACIA & UPJOHN COMPANY LLC | 2006-01-26 | — | — | US | disclosed |
| EP-1481961-A1 | PROCESS FOR PRODUCING (R)-3-HYDROXY-3-(2-PHENYLETHYL)HEXANOIC ACID AND ITS INTERMEDIATE | Sumitomo Chemical Company, Limited (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040138496-A1 | Production method of (R)-3- hydroxy-3-(2-phenylethyl)hexanoic acid and intermediate thereof | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2004-07-15 | — | — | US | disclosed |
| US-6683207-B2 | RESOLUTION USING 1-AMINO-1-PHENYLETHANE DERIVATIVE | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2004-01-27 | — | — | US | disclosed |
| US-20030176507-A1 | Production method of (R) -3 hydroxy-3- (2-phenylethyl) hexanoic acid and intermediate thereof | SUMIKA FINE CHEMICALS CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138496-A1 | Production method of (R)-3- hydroxy-3-(2-phenylethyl)hexanoic acid and intermediate thereof | HAAO, HPD, HAO2 | CASR 2564/4885LMNA 4401/4885KMT2A 2893/4885 |
| US-20060020023-A1 | Racemization method | STS, SQLE, HAO2 | CASR 2583/4885LMNA 2924/4885KMT2A 3091/4885 |
| US-20030176507-A1 | Production method of (R) -3 hydroxy-3- (2-phenylethyl) hexanoic acid and intermediate thereof | HAAO, HPD, HAO2 | CASR 2626/4885LMNA 4378/4885KMT2A 2876/4885 |
| US-20060016683-A1 | Photoracamization method | CYP3A43, CRY2, CRY1 | CASR 1093/4885LMNA 2607/4885KMT2A 2672/4885 |
| US-20060020022-A1 | Enantioselective separation method | SLC7A1, SLC10A1, DHCR7 | CASR 1648/4885LMNA 3541/4885KMT2A 3266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.